Blog Archives

Pfizer Inc.’s New Antiviral Cocktail to Combat Covid-19 Seems Likely to Turn the Tide on Hospitalizations. An Entire Industry Sector is Poised to Benefit Disproportionately as a Result.

Utilizing “off the shelf” research on SARS (Sudden Acute Respiratory Syndrome) era antivirals, Pfizer Inc (PFE-NYSE, $47.51) seems, more than likely, to have produced an elegant solution for a very pressing gap in the current approach to combatting Covid-19 infection.

Posted in Open Blog

Novo Nordisk (NVO-NYSE, $109.33) Raises 2021 Guidance by 15%, Based on Back Half of 2021 Strength.

This pre-announcement represents, what I consider to be, a significant departure from prior financial reports. Typically, management at NVO provides any guidance increases concurrent with the release of a financial report. This notification has taken place prior to the fiscal

Posted in Open Blog

Visa (V-$212.52, NYSE) and Mastercard (MA-$334.49) Beat on Earnings. Management of Visa Needs to Greatly Tighten Up on Cost Controls.

Visa reported a healthy beat on quarterly earnings but guided towards a high mid-teens revenue increase in 2022. The reduction in a forecast growth rate is yawned at by retail investors as a “nothingburger” (who would fret about a company

Posted in Open Blog

Gnostic Capital Large Cap Global Portfolio Return of 5.7% for the Quarter Ended September 30th, 2021.

For the fiscal quarter ended September 30th, the DJIA posted a return of -1.9%. The S&P 500 provided a negligible increase of .002% for the quarter and the NASDAQ reported a negligible loss (less than 4/10th of 1%) over the

Posted in Open Blog

Secular Trend Investing Demands as Much from its Investors as it offers.

“Don’t End Up in the Washing Machine”. This cryptic counsel, offered up by an impossibly lean guide heading up the overnighter to Punta San Lorenzo, Ecuador, differs from vacation hotel surf instruction tips, issued at beginner surf lessons taken at

Posted in Open Blog
Recent Comments